OXiGENE, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of product candidates that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company's products include ZYBRESTAT, which is in FALCON Trial - Phase II randomized controlled study for the treatment of 1st-line non-small cell lung cancer, as well as in Phase II Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and OXi4503 that is in Phase I dose-escalation study and Phase Ib dose-ranging study for the treatment of refractory solid tumors hepatic tumors. Its products also include ZYBRESTAT for ophthalmology, which is in phase II randomized, double-masked, placebo-controlled, and single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503.
